An efficacious and safe vaccine is needed for Tuberculosis. The goal of this project is to develop a novel TB vaccine candidate strains of M. tuberculosis and M. smegmatis. Safety is achieved by generating attenuated mutants that fail to grow in immunocompromised mice. To generate a more efficacious TB vaccine, this project will generate mutants that have enhanced immunogenicity. Enhanced immunogenicity can be achieved by identifying mutations that inactivate determinants that evade host innate and adaptive immune responses. M. tuberculosis has the ability to actively suppress the induction of THI cytokines.
Aim 1 utilizes a screen employing a macrophage cell line containing the gene encoding the green fluorescent protein fused to the IL-12 inducible promoter. Transposon and null deletion mutants of attenuated M. tuberculosis will be screened for the ability to induce IL-12. M. tuberculosis actively prevents apoptosis.
Aim 2 uses a genetic screen to identify apoptotic blocking effectors (abe) mutations. The mutants isolated in both Aim 1 and Aim 2 will be evaluated for their efficacy in protecting mice against aerosolized M. tuberculosis challenges using both M. tuberculosis H37Rv and the KZN strain from South Africa. Preliminary data for Aim 3 has identified a novel set of genes in M. smegmatis named ike for innate killing evasion. The M. smegmatis Aike deletion Mice immunized with M. smegmatis Aike mutant containing a set of M. tuberculosis genes (named IKEPLUS) elicits a bactericidal immunity against M. tuberculosis. Heterologous prime and boosts with ILEPLUS and attenuated M. tuberculosis will be explored.

Public Health Relevance

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI063537-08
Application #
8511539
Study Section
Special Emphasis Panel (ZAI1-AWA-M)
Project Start
2013-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
8
Fiscal Year
2013
Total Cost
$416,291
Indirect Cost
$165,513
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Panas, Michael W; Sixsmith, Jaimie D; White, KeriAnn et al. (2014) Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses. Infect Immun 82:5317-26
Chan, John; Mehta, Simren; Bharrhan, Sushma et al. (2014) The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin Immunol 26:588-600
Smith, Kristen L Jurcic; Saini, Divey; Bardarov, Svetoslav et al. (2014) Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model. PLoS One 9:e94953
Sixsmith, Jaimie D; Panas, Michael W; Lee, Sunhee et al. (2014) Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. Clin Vaccine Immunol 21:1385-95
Carreño, Leandro J; Kharkwal, Shalu Sharma; Porcelli, Steven A (2014) Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy 6:309-20
Tufariello, JoAnn M; Malek, Adel A; Vilchèze, Catherine et al. (2014) Enhanced specialized transduction using recombineering in Mycobacterium tuberculosis. MBio 5:e01179-14
Prados-Rosales, Rafael; Carreño, Leandro J; Batista-Gonzalez, Ana et al. (2014) Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis. MBio 5:e01921-14
Venkataswamy, Manjunatha M; Ng, Tony W; Kharkwal, Shalu S et al. (2014) Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One 9:e108383
Vilchèze, Catherine; Molle, Virginie; Carrère-Kremer, Séverine et al. (2014) Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis. PLoS Pathog 10:e1004115
Kozakiewicz, Lee; Phuah, Jiayao; Flynn, Joanne et al. (2013) The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol 783:225-50

Showing the most recent 10 out of 37 publications